espite the significant reduction in mortality achieved in clinical trials, heart failure patients still have a poor prognosis. 1 Chronic heart failure (CHF) is accompanied by a variety of pathophysiological changes that trigger deterioration of ventricular function and disease progression. 2, 3 The role of cardiac biomarkers in the evaluation and risk stratification of patients presenting with possible heart failure continues to increase in importance. Biomarkers can serve to confirm the diagnosis in symptomatic patients, help in the assessment of patients who present with nonspecific symptoms, and evaluate prognosis. 4 Brain natriuretic peptide (BNP), secreted from the left ventricle by mechanical overload, is a well-established prognostic factor in patients with CHF and a wide range of functional impairments. [5] [6] [7] Several studies have shown that heart-type fatty acid binding protein (H-FABP), a low molecular weight protein (≈15 kDa) that is abundant in the cytosolic fraction of cardiomyocytes, 8 is rapidly released into the circulation from damaged myocardium, 9-11 and the serum H-FABP concentration is increased in patients with advanced heart failure. 4, 12 We have previously demonstrated that H-FABP is a promising novel marker for myocardial cell injury and prognosis in heart failure patients, 13 and other reports also suggest that ongoing myocardial cell injury, documented by elevated serum concentrations of H-FABP, plays a critical role in the pathophysiology of CHF. [12] [13] [14] [15] The purpose of the present study was to evaluate whether the combination of a marker for myocardial cell injury (H-FABP) and one for left ventricular overload (BNP) can reliably risk stratify patients for future cardiac events.
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Methods

Study Design
We prospectively studied 186 consecutive patients (109 men, 77 women; mean age, 67±12 years, range 15-92) who had been admitted from April 1996 to April 2004 for the treatment of worsening CHF or for diagnosis and pathophysiological investigations or for therapeutic evaluation of heart failure. The diagnosis of heart failure was based on a history of dyspnea and symptomatic exercise intolerance with signs of pulmonary congestion or peripheral edema or documentation of left ventricular enlargement or dysfunction by chest X-ray, echocardiography or radionuclide ventriculography. Exclusion criteria in this study were patients with clinical or electrocardiographic evidence 
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suggestive of acute coronary syndrome within the 3 months preceding admission, those with renal failure characterized by a serum creatinine concentration ≥1.5 mg/ml, and those with active hepatic or pulmonary disease. Informed consent was obtained from all patients before participation in this study, and the protocol was approved by the institution's Human Investigations Committee.
The study population's characteristics are listed in Table 1 . The functional severity of heart failure was New York Heart Association (NYHA) class I in 53, class II in 67, class III in 57, and class IV in 9 patients. The etiologies of CHF were dilated cardiomyopathy in 69, ischemic heart disease in 49, valvular heart disease in 32, tachycardia-induced cardiomyopathy in 19 and hypertensive heart disease in 17 patients. A history of hypertension was considered present if the patient currently or had previously received medical therapy for high blood pressure. A diagnosis of diabetes and hyperlipidemia were obtained from medical records or patient history.
Blood samples were obtained at admission for measurements of both serum H-FABP and plasma BNP concentrations. Two-dimensional echocardiography was performed per routine standard of care by experts unaware of the study within 1 week of the measurement of biochemical markers. Physicians were kept unaware of the results of the biochemical markers, and optimal medical therapy was performed independently based on improvement in symptoms, physical examination findings, and pulmonary congestion on chest X-ray. 16 
Endpoints and Follow-up
No patients were lost to follow-up (mean follow-up 534± 350 days, range 5-1,080 days) after admission. Events were centrally adjudicated using medical records, autopsy reports, death certificates, and witness statements. 17, 18 The endpoints, which were judged independently by researchers, were (1) cardiac death, defined as death from worsening heart failure or sudden cardiac death, and (2) worsening heart failure requiring readmission. Sudden cardiac death was defined as death without definite premonitory symptoms or signs and was established by the attending physician.
Assay of H-FABP and BNP Concentrations
Venous blood samples were obtained on admission for measurements of serum concentrations of H-FABP. These samples were immediately centrifuged at 2,500 G for 15 min at 4°C. The clarified serum samples were frozen, stored at -70°C, and thawed just before assay. H-FABP concentrations were measured using a 2-step sandwich enzyme-linked immunosorbent assay kit (MARKIT-M H-FABP, Dainippon Pharmaceutical Co Ltd, Tokyo, Japan) as previously reported. 13, 19 The same blood samples were used for measurement of plasma BNP concentrations. The samples were transferred to chilled tubes containing 4.5 mg of ethylenediaminetetraacetic acid disodium salt and aprotinin (500 U/ml), and immediately centrifuged at 1,000 G for 15 min at 4°C. The clarified plasma samples were frozen, stored at -70°C and thawed just before assay. BNP concentrations were measured using a commercially available specific radioimmunoassay for human BNP (Shiono RIA BNP assay kit, Shionogi Co Ltd, Tokyo, Japan).
The analytical range, intra-and inter-assay coefficients of variation were, respectively, 1.1-250 ng/ml, 3.0% and 3.5% for H-FABP assay, and 4.0-2,000 pg/ml, 10.9% and 10.6% for BNP assay.
Statistical Analysis
Results are presented as the mean value ± SD for continuous variables and as the percentage of total patients for categorical variables. The independent samples t-test and chi-square test or linear regression analysis were used for comparison of continuous and categorical variables, respectively. The value below the lower detection limit of the assay was defined as zero. A Cox proportional hazard analysis was performed to determine the independent pre- dictor of cardiac events for the entire population. Significant variables selected in univariate analysis were entered into the multivariate analysis. The cardiac event-free curve was computed according to the Kaplan-Meier method, and comparison of cardiac event-free survival between subgroups was performed using the log-rank test and post hoc test with Bonferroni's adjustment. The receiver operating characteristic (ROC) curves were constructed to illustrate various cut-off values of H-FABP and BNP for predicting cardiac events at 36 months and to determine optimal sensitivity and specificity. 20 The area under the curve was calculated by the trapezoidal rule. Statistical significance was established at p<0.05 (2-sided). Statistical analysis was performed with a standard statistical program package (StatView, version 5.0, SAS Institute Inc, Cary, NC, USA).
Results
Baseline characteristics of patients are presented in Table 1 . The mean serum H-FABP and plasma BNP concentrations were 9.59±8.95 ng/ml and 863±1,134 pg/ml, respectively. H-FABP concentrations did not differ between patients with ischemic and nonischemic heart disease (4.6± 2.5 vs 5.7±4.8 ng/ml). A simple linear regression analysis showed that H-FABP concentrations weakly correlated with BNP concentrations (r=0.4620, p<0.0001) as shown in Fig 1. 
Clinical Outcomes
All patients were followed-up completely. There were 5 noncardiac deaths (2 suicides, 2 cerebral hemorrhage, 1 gastric cancer) and 44 cardiac events (23.7%), including 16 cardiac deaths (4 in-hospital) and 28 readmissions for worsening heart failure during a mean follow-up period of 534±350 days. Twenty-seven of the 44 cardiac events (61.4%) occurred within 12 months after admission (4 inhospital cardiac deaths, 9 cardiac deaths, and 18 readmissions for worsening heart failure). The causes of cardiac death were worsening CHF in 11 patients and fatal acute myocardial infarction in 2 patients. The causes of the 4 inhospital cardiac deaths were worsening CHF (3) and fatal acute myocardial infarction (1) .
Patients with cardiac events were older (p=0.0006) and had a more severe NYHA functional class (p<0.001) and higher concentrations of both H-FABP (p=0.0160) and BNP (p=0.0005) than those without cardiac events (Table 2 ). Other parameters including gender, the number of patients with ischemic heart disease and left ventricular ejection fraction were not significantly different between patients with and without cardiac events. The ROC curves for H-FABP and BNP to predict cardiac events at 36 months after admission in patients with CHF are shown in Fig 2. The area under the ROC curve for H-FABP (0.7896, 95% confidence interval (CI) 0.72-0.86) was larger than that for BNP (0.6668, 95% CI 0.57-0.76). The chi-square test yielded a significance probability of 0.0157, suggesting that there was a significant difference between these 2 areas. Thus, both the sensitivity and specificity of serum H-FABP concentration to predict cardiac events were significantly higher than for plasma BNP concentration, indicating that H-FABP is superior to BNP for predicting cardiac events in CHF patients.
The optimal values of H-FABP and BNP for predicting cardiac events were determined as those with the largest sum of sensitivity plus specificity on each of the ROC curves; H-FABP >4.3 ng/ml had a sensitivity of 84.1% and a specificity of 62.0%, and BNP >200 pg/ml had a sensitivity of 70.1% and a specificity of 61.9% (Fig 2) .
Based on these criteria from the ROC curve, H-FABP concentrations were abnormally high (>4.3 ng/ml) in 10 of the 53 patients (18.8%) in NYHA class I, in 29 of the 67 patients (43.2%) in class II, in 39 of the 57 patients (68.4%) in class III, and all the patients (9/9: 100%) in class IV (p<0.0001).
Independent Predictors of Cardiac Events
The ability of prognostic variables to predict cardiac events was examined by univariate and multivariate Cox proportional hazard analyses. Among all parameters, high H-FABP, high BNP, NYHA functional class, and age were associated with subsequent cardiac events by univariate analysis (Table 3) . Therefore, these 4 independent variables selected by the univariate analysis were entered into the multivariate analysis and of them high H-FABP (hazard ratio 5.416, p=0.0002) and high BNP (hazard ratio 2.41, p=0.0463) were the only independent predictors of cardiac events in patients with CHF. 
Risk Stratification Using a Combination of H-FABP and BNP Concentrations
As shown in Fig 1, simple linear regression analysis showed a weak correlation between the H-FABP and BNP concentrations, suggesting that these 2 parameters may have differing prognostic significance. Therefore, we divided the patients into 4 groups based on the H-FABP and BNP cut-off values: (1) normal group (n=68): H-FABP ≤4.3 ng/ml and BNP ≤200 pg/ml; (2) high BNP group (n=31): H-FABP ≤4.3 ng/ml and BNP >200 pg/ml; (3) high H-FABP group (n=33): H-FABP >4.3 ng/ml and BNP ≤200 pg/ml; (4) high H-FABP + high BNP group (n=54): H-FABP >4.3 ng/ml and BNP >200 pg/ml. The characteristics of these 4 groups are presented in Table 4 . Group 4 were older and had a higher NYHA functional class.
This classification by the combination of H-FABP >4.3 ng/ml and BNP >200 pg/ml on admission correlated with the incremental incidence in the in-hospital cardiac mortality, overall cardiac mortality, and all cardiac event rates. As shown in Fig 3, group 4 had the highest rates for cardiac death and all cardiac events (p<0.001). KaplanMeier analysis also demonstrated that the combination of H-FABP and BNP could reliably risk stratify patients for cardiac events (Fig 4) . The high H-FABP + high BNP group had the highest risk for cardiac events compared with the other groups. There was not a significant difference for cardiac events between groups 2 (high BNP) and 3 (high H-FABP) in the short term, but there was a higher tendency of risk in group 3 than in group 2 for the long term. One year event-free survival was 94%, 93%, 87%, and 61% in groups 1-4, respectively. Thus, the combination of H-FABP and BNP improved the prognostic value over either one of these parameters alone for risk stratification of CHF patients.
Discussion
The results of the present study suggest that the H-FABP and BNP concentrations at admission are independently associated with both cardiac death and nonfatal cardiac events in patients hospitalized for CHF. Combined measurement at admission of H-FABP (a marker for myocardial cell injury) and BNP (a marker for left ventricular overload) concentrations is a novel method for the risk stratification of patients with CHF for future cardiac events.
BNP release is increased as left ventricular function deteriorates, and both increased wall stretch (ie, increased volume) and increased tension (ie, increased filling pressure) are responsible for this increased secretion. Thus, BNP is a well-established prognostic indicator for heart failure patients with a wide range of functional impairments. [4] [5] [6] [7] However, it has been recently recognized that BNP concentrations do not correlate with the functional severity of heart failure, and an increased BNP concentration is frequently observed in patients with no evidence of heart failure. [21] [22] [23] [24] We and others have previously reported that the H-FABP concentration is increased in patients with advanced heart failure, and high concentrations are associated with adverse outcome. [12] [13] [14] In the present study, the sensitivity and specificity of the serum H-FABP concentration to predict cardiac events at 36 months were both significantly higher than those of plasma BNP concentration, indicating that H-FABP is superior for predicting cardiac events in CHF patients. These results also suggest that the release of H-FABP, a cytosolic marker of myocardial damage, into the circulation reflects ongoing myocardial cell injury and is associated with progression of CHF. Although the detailed mechanisms of ongoing cardiomyocyte damage are still unknown, several possible mechanisms, such as cardiomyocyte necrosis, apoptosis, microcirculatory disorder and chronic inflammation, have been suggested. 10, 14, 15 The present study showed a weak correlation between H-FABP and BNP concentrations, suggesting that these markers detect different features of the pathophysiologic process of heart failure. In the present study, the classification based on the combination of H-FABP (>4.3 ng/ml) and BNP (>200 pg/ml) on admission correlated with the incremental incidence in overall cardiac mortality and cardiac event rates. As shown in Fig 3, the high H-FABP + high BNP group had the highest rates for cardiac deaths and all cardiac events. Kaplan-Meier analysis also demonstrated that the combination of H-FABP and BNP could reliably risk stratify patients for cardiac events (Fig 4) .
It has been recently reported that the combined measurement of BNP and troponin T can predict adverse cardiac events in patients with heart failure. 25, 26 In contrast to H-FABP (a small cytosolic protein), troponin T is a myofibrillar component, and therefore H-FABP might be more sensitive to myocardial cell injury than troponin T. Further study, comparing directly which marker is more appropriate for detecting latent myocardial damage and predicting clinical outcome, is needed. In addition, because decreases in H-FABP and BNP concentrations after the treatment of acute heart failure have been reported, 15 it would be important to examine the serial changes in the concentration of these markers in our study population.
The cut-off values derived from the ROC curves are related to the study population and might differ in other sets of patients. Further studies with a greater number of patients are necessary to better delineate the prognostic value of the cardiac biomarkers studied in the present patients.
Conclusions
Our data suggest that the combined measurement of H-FABP and BNP concentrations at admission is highly reliable method of risk stratification of patients hospitalized for CHF.
